Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
Over the last 12 months, insiders at Exelixis, Inc. have bought $12.67M and sold $25.28M worth of Exelixis, Inc. stock.
On average, over the past 5 years, insiders at Exelixis, Inc. have bought $7.63M and sold $25.65M worth of stock each year.
Highest buying activity among insiders over the last 12 months: JOHNSON DAVID EDWARD (director) — $38M.
The last purchase of 225,000 shares for transaction amount of $4.67M was made by JOHNSON DAVID EDWARD (director) on 2024‑05‑30.
2024-11-22 | Sale | EVP, Commercial | 10,000 0.0035% | $35.27 | $352,700 | +2.26% | ||
2024-11-18 | Sale | EVP, Commercial | 41,588 0.0145% | $34.36 | $1.43M | +1.19% | ||
2024-11-05 | Sale | CSO/EVP Disc & Trans Research | 96,986 0.0346% | $35.00 | $3.39M | +0.41% | ||
2024-11-01 | Sale | EVP & General Counsel | 50,000 0.0175% | $34.13 | $1.71M | +4.92% | ||
2024-11-01 | Sale | director | 30,000 0.0105% | $34.00 | $1.02M | +4.92% | ||
2024-10-30 | Sale | CSO/EVP Disc & Trans Research | 1,162 0.0004% | $31.40 | $36,487 | +9.77% | ||
2024-10-28 | Sale | EVP & General Counsel | 25,000 0.0086% | $28.39 | $709,750 | +6.46% | ||
2024-09-23 | Sale | EVP & General Counsel | 25,000 0.0088% | $26.38 | $659,500 | +17.20% | ||
2024-08-26 | Sale | EVP, General Counsel & Sec | 20,000 0.007% | $25.79 | $515,800 | +4.26% | ||
2024-08-14 | Sale | director | 8,250 0.0028% | $26.56 | $219,120 | 0.00% | ||
2024-08-12 | Sale | CSO/EVP Disc & Trans Research | 20,883 0.0073% | $27.06 | $565,094 | -1.43% | ||
2024-08-09 | Sale | EVP and CFO | 125,000 0.0442% | $27.19 | $3.4M | -1.41% | ||
2024-08-08 | Sale | director | 33,725 0.0115% | $26.89 | $906,865 | -2.01% | ||
2024-08-07 | Sale | EVP, General Counsel & Sec | 80,000 0.0269% | $25.97 | $2.08M | +0.53% | ||
2024-08-07 | Sale | CSO/EVP Disc & Trans Research | 95,000 0.0307% | $25.00 | $2.38M | +0.53% | ||
2024-08-07 | Sale | EVP, Commercial | 14,000 0.0046% | $25.50 | $357,000 | +0.53% | ||
2024-06-04 | Sale | director | 8,287 0.0029% | $22.00 | $182,314 | +20.81% | ||
2024-05-30 | director | 225,000 0.0772% | $20.76 | $4.67M | +25.75% | |||
2024-05-28 | director | 200,000 0.0686% | $20.32 | $4.06M | +28.08% | |||
2024-05-21 | Sale | director | 11,686 0.004% | $20.96 | $244,939 | +23.42% |
JOHNSON DAVID EDWARD | director | 1525730 0.5343% | $36.46 | 4 | 1 | |
PAPADOPOULOS STELIOS | director | 1260578 0.4414% | $36.46 | 2 | 11 | +117.05% |
Senner Christopher J. | EVP and CFO | 721680 0.2527% | $36.46 | 0 | 12 | |
Hessekiel Jeffrey | EVP & General Counsel | 530325 0.1857% | $36.46 | 0 | 36 | |
Aftab Dana | CSO/EVP Disc & Trans Research | 498945 0.1747% | $36.46 | 0 | 6 | |
WYSZOMIERSKI JACK L | director | 349499 0.1224% | $36.46 | 0 | 10 | |
Haley Patrick J. | EVP, Commercial | 278665 0.0976% | $36.46 | 0 | 53 | |
POSTE GEORGE | director | 169020 0.0592% | $36.46 | 0 | 12 | |
Freire Maria C | director | 91007 0.0319% | $36.46 | 0 | 2 | |
Garber Alan M | director | 35703 0.0125% | $36.46 | 0 | 13 | |
Smith Julie | director | 5445 0.0019% | $36.46 | 0 | 1 | |
DUYK GEOFFREY M | Pres R&D & CSO | 941355 0.3296% | $36.46 | 0 | 19 | |
SCANGOS GEORGE A | director | 714717 0.2503% | $36.46 | 1 | 243 | +51.69% |
Schwab Gisela | Pres, Prod Dev & Med Aff & CMO | 614078 0.215% | $36.46 | 1 | 37 | +9.5% |
FORMELA JEAN FRANCOIS | director | 584519 0.2047% | $36.46 | 0 | 26 | |
WILLSEY LANCE | 424415 0.1486% | $36.46 | 12 | 12 | +142.31% | |
Lamb Peter | EVP, Scientific Strategy & CSO | 410958 0.1439% | $36.46 | 0 | 27 | |
SATO GLEN Y | CFO Sec and General Counsel | 258266 0.0904% | $36.46 | 0 | 1 | |
COHEN CHARLES | director | 181375 0.0635% | $36.46 | 0 | 11 | |
STALDER PETER | director | 96458 0.0338% | $36.46 | 0 | 2 | |
MORRISSEY MICHAEL | President and CEO | 85985 0.0301% | $36.46 | 1 | 60 | +201.22% |
MARCHESI VINCENT T | director | 66115 0.0232% | $36.46 | 13 | 13 | +2.14% |
KARBE FRANK | EVP & CFO | 60110 0.021% | $36.46 | 3 | 0 | +92.47% |
FELDBAUM CARL B | director | 18701 0.0065% | $36.46 | 0 | 12 | |
FISHERMAN JASON S | 7881 0.0028% | $36.46 | 0 | 2 | ||
BALL KRISTINE M | Controller & Interim CFO | 4913 0.0017% | $36.46 | 0 | 2 | |
Heller Frances K | EVP, Business Development | 1500 0.0005% | $36.46 | 0 | 2 | |
SIMONTON PAMELA A | SVP, Patents & Licensing | 0 0% | $36.46 | 0 | 8 | |
RIVERA LUPE M | EVP, Operations | 0 0% | $36.46 | 0 | 6 |
BlackRock | $827.76M | 11.98 | 34.88M | -3.14% | -$26.86M | 0.02 | |
The Vanguard Group | $731.35M | 10.58 | 30.82M | -2.69% | -$20.2M | 0.01 | |
Farallon Capital | $633.08M | 9.16 | 26.68M | +0.17% | +$1.04M | 4.45 | |
Renaissance Technologies | $358.36M | 5.18 | 15.1M | -3.29% | -$12.2M | 0.57 | |
State Street | $310.42M | 4.49 | 13.08M | +0.37% | +$1.15M | 0.01 | |
JPMorgan Chase | $126.34M | 1.83 | 5.32M | -31.23% | -$57.37M | 0.01 | |
Geode Capital Management | $124.41M | 1.8 | 5.24M | +1.87% | +$2.29M | 0.01 | |
Dimensional Fund Advisors | $113.6M | 1.64 | 4.79M | +4.97% | +$5.38M | 0.03 | |
Morgan Stanley | $111.38M | 1.61 | 4.69M | -1.69% | -$1.92M | 0.01 | |
Nuveen | $95.07M | 1.38 | 4.01M | +15.16% | +$12.51M | 0.03 | |
Stephens Investment Management Group LLC | $92.87M | 1.34 | 3.91M | -4.7% | -$4.58M | 1.24 | |
Charles Schwab | $79.94M | 1.16 | 3.37M | +0.12% | +$98,360.85 | 0.02 | |
T. Rowe Price | $79.22M | 1.15 | 3.34M | -8.53% | -$7.39M | 0.01 | |
First Trust | $70.56M | 1.02 | 2.97M | -5.68% | -$4.25M | 0.07 | |
AQR Capital | $69.09M | 1 | 2.91M | +33.63% | +$17.39M | 0.11 | |
BNY Mellon | $65.86M | 0.95 | 2.78M | -7.39% | -$5.25M | 0.01 | |
LSV Asset Management | $65.84M | 0.95 | 2.77M | +1,651.39% | +$62.08M | 0.14 | |
Fuller & Thaler Asset Management, Inc. | $63.08M | 0.91 | 2.66M | +1.65% | +$1.02M | 0.28 | |
Los Angeles Capital Management LLC | $58.24M | 0.84 | 2.45M | +948.27% | +$52.68M | 0.19 | |
Jacobs Levy Equity Management | $57.09M | 0.83 | 2.41M | +1.74% | +$973,784.28 | 0.21 | |
Jupiter Fund Management | $53.82M | 0.78 | 2.27M | +148.17% | +$32.13M | 0.15 | |
Meditor Group Ltd | $52.18M | 0.76 | 2.2M | -16.66% | -$10.43M | 76.68 | |
Fidelity Investments | $46.57M | 0.67 | 1.96M | -36.12% | -$26.33M | <0.01 | |
CalPERS | $45.94M | 0.67 | 1.94M | -1.95% | -$912,869.37 | 0.03 | |
Bellevue Group | $45.16M | 0.65 | 1.9M | -9.72% | -$4.86M | 0.69 | |
Northern Trust | $45.06M | 0.65 | 1.9M | -14.42% | -$7.59M | 0.01 | |
Ameriprise Financial | $44.91M | 0.65 | 1.89M | +1.81% | +$798,445.42 | 0.01 | |
Assenagon Asset Management S.A. | $41.92M | 0.61 | 1.77M | -9.38% | -$4.34M | 0.1 | |
Two Sigma Advisers LP | $41.67M | 0.6 | 1.76M | -4.6% | -$2.01M | 0.07 | |
Krensavage Asset Management LLC | $37.16M | 0.54 | 1.57M | -17.53% | -$7.9M | 18.76 | |
Russell Investments Group Ltd | $36.42M | 0.53 | 1.53M | +1.38% | +$496,089.46 | 0.05 | |
Brandywine Global Investment Management | $36.09M | 0.52 | 1.52M | +6.05% | +$2.06M | 0.26 | |
Psquared Asset Management AG | $34.84M | 0.5 | 1.47M | +5.55% | +$1.83M | 10.51 | |
Invesco | $31.67M | 0.46 | 1.33M | -24.55% | -$10.3M | 0.01 | |
Allspring Global Investments | $30.35M | 0.44 | 1.28M | -7.33% | -$2.4M | 0.05 | |
Acadian Asset Management | $28.9M | 0.42 | 1.22M | -31.24% | -$13.13M | 0.1 | |
Systematic Financial Management LLC | $26.84M | 0.39 | 1.13M | -0.36% | -$96,106.55 | 0.76 | |
Caligan Partners LP | $26.12M | 0.38 | 1.1M | +20.86% | +$4.51M | 6.9 | |
Bank of America | $24.39M | 0.35 | 1.03M | -35.42% | -$13.38M | <0.01 | |
Woodline Partners LP | $23.42M | 0.34 | 987,094 | 0% | +$0 | 0.2 | |
Goldman Sachs | $21.51M | 0.31 | 906,284 | -13.59% | -$3.38M | <0.01 | |
RhumbLine Advisers | $21.11M | 0.31 | 889,688 | -5.83% | -$1.31M | 0.02 | |
Franklin Templeton Investments | $20.46M | 0.3 | 862,224 | +98.45% | +$10.15M | 0.01 | |
Blair William Co Il | $18.01M | 0.26 | 758,969 | +1.19% | +$212,454.80 | 0.06 | |
Candriam S C A | $17.93M | 0.26 | 755,477 | +6.16% | +$1.04M | 0.12 | |
Two Sigma | $17.59M | 0.25 | 741,123 | +28.86% | +$3.94M | 0.03 | |
Legal & General | $16.02M | 0.23 | 675,052 | -7.64% | -$1.32M | <0.01 | |
Man Group Plc | $15.63M | 0.23 | 658,859 | -13.46% | -$2.43M | 0.04 | |
Ubs Asset Management Americas Inc | $14.68M | 0.21 | 618,552 | -0.32% | -$46,819.29 | 0.01 | |
EULAV Asset Management | $14.48M | 0.21 | 610,000 | -6.15% | -$949,200.00 | 0.4 |